Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Phase 1

Active, not recruiting

• Conditions: Solid Tumors; Lymphoma
• Interventions: Drug: ASTX660

• Registration Number: NCT02503423
• Lead Sponsor: Taiho Oncology, Inc.

Brief Summary

This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.

Detailed Description

ASTX660 is a synthetic small molecule dual antagonist of cellular inhibitor of apoptosis protein (cIAP) 1 and X-linked inhibitor of apoptosis protein (XIAP) that has been shown to have potent proapoptotic and tumor growth inhibitory activity in nonclinical models. The Phase 1 portion of the study (completed) will determine the MTD, RP2D, and recommended dosing regimen. The Phase 2 portion will evaluate activity in selected tumor types. Subjects will continue to receive their assigned treatment throughout the study until the occurrence of disease progression, death, or unacceptable treatment-related toxicity, or until the study is closed by the sponsor.

Study Timeline

• Study Start: 2015-07
• Study First Submitted: 2015-07-02
• Study First Submitted QC: 2015-07-17
• Study First Posted: 2015-07-21
• Primary Completion: 2022-10
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-05
• Last Update Posted: 2025-01-07
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 230

Inclusion Criteria

1. Able to understand and comply with the protocol and study procedures, understand the risks involved in the study, and provide written informed consent before any study-specific procedure is performed.

2. Men and women 18 years of age or older.

3. Subjects with histologically or cytologically confirmed advanced solid tumors or lymphoma that is metastatic or unresectable, and for whom standard life-prolonging measures are not available. Specific tumor types that will be selected for study in Phase 2 are detailed in the protocol.

   a. For Phase 2 Cohort 3, subjects must have histologically confirmed PTCL (local pathology report) as defined by 2016 World Health Organization (WHO) classification. The following subtypes are eligible for the study: adult T-cell lymphoma/leukemia, extranodal natural killer (NK)/T-cell lymphoma nasal type, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, hepatosplenic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma, nodal peripheral T-cell with T-follicular helper (THF) phenotype, and anaplastic large-cell lymphoma.

4. For Phase 2 Cohorts 3 and 4, patients must have evidence of documented progressive disease and must have received at least two prior systemic therapies.

   1. Subjects with CD30-positive lymphoma must have received, be ineligible for, or intolerant to brentuximab vedotin, provided that brentuximab vedotin is locally approved and available.
   2. Subjects with mycosis fungoides or Sezary syndrome must have received, be ineligible or intolerant to mogamulizumab, provided that mogamulizumab is locally approved and available.

5. In the Phase 2 portion of the protocol only, subjects must have measurable disease according to response criteria appropriate for their type of cancer.

   a. For Phase 2 Cohort 3 (PTCL), measurable disease by contrast-enhanced diagnostic CT (at least 1 nodal lesion >1.5 cm or extranodal lesions >1.0 cm) is required.

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

7. Acceptable organ function, as evidenced by the following laboratory data:

   1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.0 * upper limit of normal (ULN).

   2. Total serum bilirubin <=1.5 * ULN

   3. Absolute neutrophil count (ANC):

      • Phase 1 and 2 (except Phase 2 subjects with known lymphoma; ie, not applicable for Cohorts 3 or 4) >=1500 cells/mm3
      • Phase 2 subjects with known lymphoma: >=1000 cells/mm3 (>750 cell/mm3 for subjects with lymphoma in bone marrow)

   4. Platelet count:

      • Phase 1 and 2 (except Phase 2 subject with known lymphoma; ie, not applicable for Cohorts 3 or 4) >=100,000 cells/mm3
      • Phase 2 subjects with known lymphoma: >= 50,000 cells/mm3; >=25,000 cells/mm3 for subjects with lymphoma in bone marrow

   5. Serum creatinine levels <= 1.5 * ULN, or calculated (by Cockcroft-Gault formula or other accepted formula) or measure creatinine clearance >=50 mL/min.

   6. Amylase and lipase <=ULN.

8. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]; see protocol for details) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures of birth control (as described in the protocol) and must agree not to become pregnant or father a child while receiving treatment with study drug and for at least 3 months after completing treatment. Contraceptive measures which may be considered highly effective comprise combined hormonal contraception (oral, vaginal, or transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence, and surgically successful vasectomy. Abstinence is acceptable only if it is consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of birth control.

Exclusion Criteria

1. Hypersensitivity to ASTX660, excipients of the drug product, or other components of the study treatment regimen.

2. Poor medical risk because of systemic diseases (e.g. active uncontrolled infections) in addition to the qualifying disease under study.

3. Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise subject safety or the integrity of the study outcomes, or interfere with the absorption or metabolism of ASTX660.

4. History of, or at risk for, cardiac disease, as evidenced by 1 or more of the following conditions:

   1. Abnormal left ventricular ejection fraction (LVEF; <50%) or echocardiogram ECHO or multiple gated acquisition scan (MUGA).
   2. Congestive cardiac failure of >= Grade 3 severity according to New York Heart Association (NYHA) functional classification defined as subjects with marked limitation of activity and who are comfortable only at rest.
   3. Unstable cardiac disease including angina or hypertension as defined by the need for overnight hospital admission within the last 3 months (90 days).
   4. History or presence of complete left bundle branch block, heart block, cardiac pacemaker or significant arrhythmia.
   5. Concurrent treatment with any medical that prolongs QT interval and may induce torsades de pointes, and which cannot be discontinued at least 2 weeks before treatment with ASTX660. [Applies to Phase 1 only].
   6. Personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy.
   7. Screening 12-lead ECG with measurable QTc interval (according to either Fridericia's or Bazett's correction) of >=470 msec).
   8. Any other condition that, in the opinion of the investigator, could put the subject at increased cardiac risk.

5. Known history of human immunodeficiency virus (HIV) infection, or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.

6. Grade 2 or greater neuropathy [Applies to Phase 1]. Grade 3 or greater neuropathy [Applies to Phase 2].

7. Known brain metastases, unless stable or previously treated.

8. Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol treatment or assessments.

9. Prior anticancer treatments or therapies within the indicated time window prior to first dose of study treatment (ASTX660), as follows:

   1. Cytotoxic chemotherapy or radiotherapy within 3 weeks prior and any encountered treatment-related toxicities (excepting alopecia) not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase 2].
   2. Skin directed treatments, including topicals and radiation within 2 weeks prior.
   3. Monoclonal antibodies within 4 weeks prior and any encountered treatment-related toxicities not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase 2].
   4. Small molecules or biologics (investigational or approved) within the longer of 2 weeks or 5 half-lives prior to study treatment and any encountered treatment-related toxicities not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase 2].
   5. At least 6 weeks must have elapsed since CAR-T infusion and subjects must have experienced disease progression, and not have residual circulating CAR-T cells in peripheral blood (based on local assessment). Any encountered treatment-related toxicities must have resolved to Grade ≤1.

10. Concurrent second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy or superficial bladder cancer [Phase 2].

11. Known central nervous system (CNS) lymphoma [Phase 2].

12. Patients with a history of allogenic transplant must not have ≥Grade 3 graft-versus-host disease (GVHD) or any clinically significant GVHD requiring systemic immunosuppression [Phase 2].

13. Systemic corticosteroids >20 mg prednisone equivalent (unless patient has been taking a continuous dose for >3 weeks prior to study entry and there is documented radiological progression) [Phase 2]. Stable dose of medium or low potency topical corticosteroids for at least 3 weeks prior to study entry are permitted [Phase 2].

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Phase 1 - Part 2 (completed)	ASTX660	Dose-expansion stage to confirm tolerability of ASTX660 at the RP2D using the every-other-week daily dosing regimen. Up to a total of 12 subjects (including the 3 or 6 subjects treated at the RP2D in Part 1) will be treated at the RP2D.
Phase 1 - Part 3 (optional)	ASTX660	The purpose of the optional Part 3 is to allow for exploration of an alternative dosing regimen of ASTX660 based on emerging safety, PK, and pharmacodynamic (PD) data from Parts 1 and 2 (using the original every-other-week dosing regimen), with agreement of the DSRC. If Part 3 is conducted, the plan is to enroll up to 18 evaluable subjects in 1 or more cohorts using a standard 3+3 study design.
Phase 2 - Cohort 1	ASTX660	Treatment with ASTX660 for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) not responsive or relapsed after standard therapy.
Phase 2 - Cohort 3	ASTX660	Treatment with ASTX660 for progressive or relapsed peripheral T-cell lymphoma (PTCL).
Phase 2 - Cohort 4	ASTX660	Treatment with ASTX660 for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Phase 2 - Cohort 6	ASTX660	Treatment with ASTX660 for cervical carcinoma not responsive or relapsed after standard therapy.
Phase 1 - Part 1 (completed)	ASTX660	Dose-escalation stage to identify the MTD and the RP2D, defined as either the MTD or a dose below the MTD that the Data and Safety Review Committee (DSRC) agree shows adequate pharmacological evidence of target engagement and/or clinical activity. Subjects will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, \[7 days on/ 7 days off\] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RP2D is determined.
Phase 2 - Cohort 2	ASTX660	Treatment with ASTX660 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Phase 2 - Cohort 5	ASTX660	Treatment with ASTX660 for other tumor types that are characterized by a molecular feature that may confer sensitivity to ASTX660 (eg, oncogenic activation of the NF-κB pathway or documented amplification of the gene loci encoding c-IAP1 or c-IAP2), pending confirmation in writing by the Astex medical monitor.

Primary Outcome Measures

Name	Time	Method
Efficacy (Phase 2) - antitumor activity assessed by objective response rate (ORR)	Up to 84 months	Antitumor activity by objective response rate
Efficacy (Phase 2) - antitumor activity assessed by disease control rate (DCR)	Up to 84 months	Antitumor activity by disease control rate
Safety (Phase 1) - number of subjects with AEs, DLTs, abnormal clinical laboratory values or physical exam results	Up to 78 months	Incidence of dose-limiting toxicities (DLTs) and other adverse events (AEs)

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetic outcome of concentration-time curve (AUC)	First 9 weeks of study treatment	Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC).
Pharmacokinetic outcome of maximum concentration (Cmax)	First 9 weeks of study treatment	Assessment of pharmacokinetic parameter maximum concentration (Cmax).
Pharmacokinetic outcome of minimum concentration (Cmin)	First 9 weeks of study treatment	Assessment of pharmacokinetic parameter minimum concentration (Cmin).
Pharmacokinetic outcome of time to maximum concentration (Tmax)	First 9 weeks of study treatment	Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)
Pharmacokinetic outcome of analysis of ASTX660 metabolites if applicable	First 9 weeks of study treatment	Assessment of pharmacokinetic parameter analysis of ASTX660 metabolites if applicable.
Progression-free survival	Up to 84 months	Number of days from the start of the study treatment to disease progression or death, whichever occurs first.
Pharmacokinetic outcome of samples over time	First 9 weeks of study treatment	Assessment of pharmacokinetic parameter of other secondary PK parameters of ASTX660 if data permit.
Assessment of target (cIAP1) engagement	Up to 84 months	Percentage degradation of cIAP1 protein in PBMCs from baseline, in response to ASTX660 treatment.
Duration of antitumor response	Up to 84 months	Time from the date of the earliest assessment of complete response or partial response to the date of relapse or death, whichever occurs earlier, or the last efficacy assessment date for subjects without a relapse or death.
Overall survival	Up to 84 months	Number of days from the day the subject received the first study treatment to the date of death, regardless of cause.

Trial Locations

Locations (68)

West Penn Hospital; 🇺🇸 Pittsburgh, Pennsylvania, United States

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

University of Washington, Seattle Cancer Care Alliance; 🇺🇸 Seattle, Washington, United States

Tufts Medical Center; 🇺🇸 Boston, Massachusetts, United States

Rochester Skin Lymphoma Medical Group; 🇺🇸 Rochester, New York, United States

Roswell Park Cancer Institute; 🇺🇸 Buffalo, New York, United States

Summit Medical Group - Florham Park Campus/Atlantic Health; 🇺🇸 Florham Park, New Jersey, United States

Emory University winship Cancer Institute; 🇺🇸 Atlanta, Georgia, United States

CliniCore Texas; 🇺🇸 Houston, Texas, United States

Institut Catala d'Oncologia; 🇪🇸 Girona, Giona, Spain

New York Presbyterian Hospital Columbia University Medical Center; 🇺🇸 New York, New York, United States

Hospital Universitario 12 de Octubre; 🇪🇸 Madrid, Spain

The Ohio State University and Wexner Medical Center, James Cancer Hospital; 🇺🇸 Columbus, Ohio, United States

Institut Bergonié, Unicancer; 🇫🇷 Bordeaux, France

Institut Universitaire du Cancer - Oncopôle, Department d'Hématologie; 🇫🇷 Toulouse Cedex 9, France

Jewish General Hospital; 🇨🇦 Montréal, Quebec, Canada

Dartmouth-Hitchcock Medical Center (DHMC); 🇺🇸 Lebanon, New Hampshire, United States

Szabolcs-Szatmár-Bereg Megyei Kórházak És Egyetemi Oktatókórház; 🇭🇺 Nyíregyháza, Hungary

Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant Orsola-Malpighi; 🇮🇹 Bologna, Italy

Azienda Socio Santaria Territoriale Monza- Osperdale San Gerado; 🇮🇹 Monza, Italy

Centre Henri Becquerel, Hematology; 🇫🇷 Rouen, France

CRU de Tours - Hôpital Bretonneau, Hématologie -Thérapy Cellulaire; 🇫🇷 Tours, France

Centre Antoine Lacassagne, Oncologie Médicale; 🇫🇷 Nice, France

Hospital Universitario Fundacion Jimenez Diaz Preview; 🇪🇸 Madrid, Spain

Gustave Roussy Cancer Campus (IGR); 🇫🇷 Villejuif, Cedex, France

Guy's and Saint Thomas' NHS Foundation Trust; 🇬🇧 London, United Kingdom

START- South Texas Accelerated Research Therapeutics; 🇺🇸 San Antonio, Texas, United States

Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne; 🇧🇪 Yvoir, Namur, Belgium

Universitair Ziekenhuis Gent; 🇧🇪 Gent, Oost-Vlaanderen, Belgium

Debreceni Egyetem Klinikai Központ; 🇭🇺 Debrecen, Hungary

Semmelweis Egyetem - I. sz. Belgyógyászati Klinika; 🇭🇺 Budapest, Hungary

The Royal Marsden NHS Foundation Trust; 🇬🇧 Sutton, Surrey, United Kingdom

Icahn School of Medicine at Mount Sinai; 🇺🇸 New York, New York, United States

British Columbia Cancer Agency; 🇨🇦 Vancouver, British Columbia, Canada

Churchill Hospital, Oxford University Hospital NHS Trust; 🇬🇧 Oxford, Oxfordshire, United Kingdom

University College London Hospitals NHS Foundation Trust; 🇬🇧 London, United Kingdom

University Hospital Southhampton NHS Foundation Trust - Somers Cancer Research; 🇬🇧 Southampton, Hampshire, United Kingdom

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia; 🇮🇹 Brescia, Italy

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

University of Oklahoma Stephenson Cancer Center; 🇺🇸 Oklahoma City, Oklahoma, United States

Oregon Health and Science University; 🇺🇸 Portland, Oregon, United States

Vanderbilt Ingram Cancer Center; 🇺🇸 Nashville, Tennessee, United States

Tom Baker Cancer Centre; 🇨🇦 Calgary, Alberta, Canada

Nova Scotia Health Athority-Qeii HSC; 🇨🇦 Halifax, Nova Scotia, Canada

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada

University Hospitals of Leicester NHS Trust; 🇬🇧 Leicester, East Midlands, United Kingdom

Sunnybrook Hospital; 🇨🇦 Toronto, Ontario, Canada

HonorHealth Research Institute; 🇺🇸 Scottsdale, Arizona, United States

USC/Norris Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States

The Sidney Kimmel Comprehensive Cancer Center at John Hopkins; 🇺🇸 Baltimore, Maryland, United States

Cedars-Sinai Medical Center; 🇺🇸 Los Angeles, California, United States

Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 🇺🇸 Chicago, Illinois, United States

Dana-Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States

New York University Langone Medical Center; 🇺🇸 New York, New York, United States

Intitut Jules Boredt; 🇧🇪 Bruxelles, Belgium

Cancer Care Manitoba; 🇨🇦 Winnipeg, Manitoba, Canada

Centre Hospitalier Lyon Sud; 🇫🇷 Pierre-Bénite, Lyon, France

Instituto Europeo di Oncologia; 🇮🇹 Milan, Italy

imCORE - Clínica Universidad de Navarra; 🇪🇸 Pamplona, Navarra, Spain

Beatson Cancer Center and University of Glasgow; 🇬🇧 Glasgow, United Kingdom

University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital; 🇬🇧 Birmingham, United Kingdom

The Christie NHS Foundation Trust, Christie Hospital; 🇬🇧 Manchester, United Kingdom

UC Davis Medical Center; 🇺🇸 Sacramento, California, United States

Simlow Cancer Hospital at Yale; 🇺🇸 New Haven, Connecticut, United States

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States

Wake Forest Baptist Health; 🇺🇸 Winston-Salem, North Carolina, United States

Hollings Cancer Center; 🇺🇸 Charleston, South Carolina, United States

Virgina Commonwealth University; 🇺🇸 Richmond, Virginia, United States